Rancherho - We've been through all those presentations and papers more than once. Without being too pedantic about this, it is always a danger to reason informally about these data based on just sketchy statistics such as medians.
I'll just mention that it is possible to put the data in the Petrylak's presentation and the integrated data together to approximate which patients actually took Taxotere. For example, from there, you can then estimate the effect of Provenge alone against placebo alone. If you've done that, you might see that Provenge worked fairly well. But even then, you still run into the issue that the subgroups that took Taxotere were self-selecting and so were the complements of those subgroups. That put into questions these results.
That said, there have been a substantial amount of work done at the NCI on combining Taxotere with different vaccines to indicate that this type of combinations might prove to be efficacious.
